Are there risks of using public clinical trial data under GDPR?

Given that clinical trial documents contain personally identifying health information about trial participants, it is necessary to anonymize these documents. While there are efforts among the agencies to harmonize their anonymization guidance and practices, they are governed by different privacy laws and are implementing quite a different anonymization methodology. This raises the question of what the risks would be to the users of these public clinical trial documents if the anonymization performed for a public data release was not adequate and the public documents still have a high risk of re-identification?

Read full article: Are there risks of using public clinical trial data under GDPR?

>